Date: 2013-03-06
Type of information: Private placement
Company: Active Biotech (Sweden)
Investors: Investor AB (Sweden)
Amount: SEK 270 million (€ 32.5 million)
Funding type: private placement
Planned used: The issue proceeds are intended to be used to strengthen Active Biotech\'s capital base and to enable the continued development and value-growth of the project portfolio, of which TASQ is financed under the partner agreement with Ipsen Pharma, whilst 57-57, ANYARA and ISI are managed and financed on a proprietary basis. The development of laquinimod and RhuDex are managed and financed by partners. The new issue also strengthens Active Biotech\'s position in discussions with potential partners.
Others: * On March 6, 2013, Active Biotech has announced that its Board of Directors has, based on the 2012 annual general meeting\'s authorization, resolved to issue in total 6,000,000 new shares in Active Biotech to Investor AB. The shares are issued at a subscription price of SEK 45 per share, providing the company with in total approximately SEK 270 million after transaction costs. The closing price for the Active Biotech share on NASDAQ OMX Stockholm on March 5, 2013 was SEK 48.80.
Through the new issue, the number of shares in Active Biotech will increase by 6,000,000 from 68,923,582 to 74,923,582 and the share capital will increase by SEK 22,616,055.93 from SEK 259,796,597.53 to SEK 282,412,653.46. Investor\'s holding will correspond to approximately 8 percent of the shares and votes in Active Biotech.
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Cancer - Oncology - Neurodegenerative diseases
